Last reviewed · How we verify
Anti-Thymocyte Globulins
Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to and eliminating thymus-derived T cells, suppressing the adaptive immune response.
Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to and eliminating thymus-derived T cells, suppressing the adaptive immune response. Used for Prevention of acute rejection in organ transplantation (renal, cardiac, hepatic), Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.
At a glance
| Generic name | Anti-Thymocyte Globulins |
|---|---|
| Also known as | ATG |
| Sponsor | Tianjin First Central Hospital |
| Drug class | Polyclonal antibody; immunosuppressant |
| Target | T lymphocyte surface antigens (CD2, CD3, CD4, CD8, and other T cell markers) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Hematology/Transplantation |
| Phase | FDA-approved |
Mechanism of action
ATG is a polyclonal antibody preparation derived from immunized animals (typically rabbits or horses) that targets multiple epitopes on T cell surfaces. It binds to T lymphocytes and causes their destruction through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, resulting in profound T cell depletion. This immunosuppressive effect is used to prevent graft rejection and treat autoimmune conditions.
Approved indications
- Prevention of acute rejection in organ transplantation (renal, cardiac, hepatic)
- Treatment of aplastic anemia
- Graft-versus-host disease (GVHD) prophylaxis and treatment
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection (opportunistic)
- Rash
- Dyspnea
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Thymocyte Globulins CI brief — competitive landscape report
- Anti-Thymocyte Globulins updates RSS · CI watch RSS
- Tianjin First Central Hospital portfolio CI